Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

Cytokines in the Treatment of Cancer

(2018) Kevin C. Conlon et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Vanesa Gregorc et al.   LANCET ONCOLOGY

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy

(2017) Roberto De Luca et al.   MOLECULAR CANCER THERAPEUTICS

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

(2017) Thomas Kammertoens et al.   NATURE

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

(2017) Anje Cauwels et al.   OncoImmunology

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

(2015) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systemic use of tumor necrosis factor alpha as an anticancer agent

(2015) Nicholas J. Roberts et al.   Oncotarget

Armed antibodies for cancer treatment: a promising tool in a changing era

(2014) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity

(2014) A. Krippner-Heidenreich et al.   JOURNAL OF IMMUNOLOGY

High efficiency cell-specific targeting of cytokine activity

(2014) Geneviève Garcin et al.   Nature Communications

Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium

(2013) Filip Van Hauwermeiren et al.   JOURNAL OF CLINICAL INVESTIGATION

The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF

(2012) Kathrin Schwager et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tumor-targeted TNF  stabilizes tumor vessels and enhances active immunotherapy

(2012) A. Johansson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology